While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Fox News senior medical analyst Dr. Marc Siegel weighs in on President Donald Trump's pharmaceutical executive order aiming to cut drug prices for Americans. Feeling snacky? Everyone knows you can ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...